Prognosis

Covid-19 Clinical Trials Aren’t Very Diverse and That’s a Problem

Laboratory equipment sits on shelves at the Moderna Therapeutics facility in Cambridge, Massachusetts.Photographer: Adam Glanzman/Bloomberg
Lock
This article is for subscribers only.

Black and Latino people have suffered far more from the novel coronavirus than other races, yet so far they account for only a small fraction of participants in human clinical trials of treatments and vaccines.

That may complicate defeating Covid-19 since drug responses can be influenced by factors tied to race and ethnicity, such as genetics. More than that, diversity in research is necessary to understand the biological underpinnings of diseases that, for example, make some people more susceptible or responsive to treatment.